Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer

Trial Profile

Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Merck Serono
  • Most Recent Events

    • 08 Sep 2017 Primary endpoint has been met. (Progression-free survival rate (Assessed at 6 and 12 months.)) as per results published in the Annals of Oncology
    • 08 Sep 2017 Results (data cut off: 30 Jun 2017) published in the Annals of Oncology
    • 08 Sep 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top